X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7121) 7121
Newsletter (70) 70
Magazine Article (25) 25
Book Chapter (19) 19
Government Document (7) 7
Dissertation (6) 6
Newspaper Article (3) 3
Book / eBook (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (3674) 3674
humans (3658) 3658
animals (3436) 3436
female (2215) 2215
cholinesterase inhibitors - pharmacology (1924) 1924
rats (1921) 1921
pharmacology & pharmacy (1734) 1734
cholinesterase inhibitors - therapeutic use (1683) 1683
cholinesterase inhibitors - administration & dosage (1535) 1535
alzheimer's disease (1501) 1501
alzheimer disease - drug therapy (1326) 1326
aged (1276) 1276
neurosciences (1237) 1237
cholinesterase inhibitors (1222) 1222
alzheimers-disease (1095) 1095
acetylcholinesterase (1052) 1052
dose-response relationship, drug (1042) 1042
dementia (996) 996
toxicology (964) 964
middle aged (919) 919
donepezil (896) 896
mice (821) 821
acetylcholinesterase - metabolism (802) 802
adult (792) 792
cholinesterase inhibitors - toxicity (757) 757
cholinesterase (676) 676
clinical neurology (673) 673
time factors (673) 673
cholinesterase inhibitors - adverse effects (669) 669
psychiatry (661) 661
brain (645) 645
rivastigmine (608) 608
rats, wistar (607) 607
treatment outcome (607) 607
brain - drug effects (599) 599
aged, 80 and over (598) 598
cholinesterase-inhibitors (594) 594
double-blind (569) 569
rats, sprague-dawley (557) 557
acetylcholine (544) 544
drug therapy (539) 539
geriatrics & gerontology (477) 477
analysis (466) 466
memory (443) 443
efficacy (422) 422
brain - enzymology (417) 417
research (417) 417
indans - therapeutic use (412) 412
piperidines - therapeutic use (406) 406
neurology (393) 393
biochemistry & molecular biology (389) 389
alzheimers disease (384) 384
double-blind method (375) 375
inhibition (365) 365
oxidative stress (353) 353
administration, oral (352) 352
brain - metabolism (351) 351
toxicity (351) 351
cholinesterases - blood (336) 336
galantamine (334) 334
cholinesterase inhibitors - pharmacokinetics (331) 331
rat (327) 327
cholinesterase inhibitors - chemistry (325) 325
disease models, animal (313) 313
care and treatment (312) 312
medicine & public health (311) 311
alzheimer’s disease (306) 306
drugs (296) 296
physostigmine - pharmacology (294) 294
piperidines - pharmacology (292) 292
anesthesiology (288) 288
physostigmine (287) 287
drug interactions (285) 285
placebo-controlled trial (283) 283
dosage and administration (280) 280
piperidines - administration & dosage (279) 279
enzyme inhibitors (278) 278
cholinesterase inhibitor (277) 277
indans - administration & dosage (277) 277
enzymes (276) 276
indans - pharmacology (276) 276
acetylcholine - metabolism (272) 272
health aspects (270) 270
soman (270) 270
insecticides - toxicity (265) 265
pharmacology/toxicology (265) 265
cholinesterases - metabolism (264) 264
behavior, animal - drug effects (262) 262
cognition - drug effects (261) 261
memantine (261) 261
pharmacokinetics (261) 261
acetylcholinesterase inhibitors (259) 259
chemistry, medicinal (258) 258
adolescent (247) 247
neuropsychological tests (247) 247
butyrylcholinesterase (246) 246
drug administration schedule (246) 246
drug therapy, combination (246) 246
dementia - drug therapy (243) 243
rodents (238) 238
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6916) 6916
Russian (101) 101
Japanese (98) 98
German (70) 70
French (39) 39
Spanish (26) 26
Italian (16) 16
Chinese (13) 13
Czech (11) 11
Polish (9) 9
Norwegian (8) 8
Dutch (6) 6
Portuguese (6) 6
Bulgarian (3) 3
Danish (3) 3
Hungarian (3) 3
Korean (3) 3
Hebrew (2) 2
Serbian (2) 2
Arabic (1) 1
Croatian (1) 1
Finnish (1) 1
Romanian (1) 1
Slovak (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2018, Volume 319, Issue 2, pp. 130 - 142
...; final follow-up on January 12, 2017. INTERVENTIONS: Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment... 
DONEPEZIL | 5-HT6 RECEPTOR ANTAGONIST | MODERATE | MEDICINE, GENERAL & INTERNAL | DOUBLE-BLIND | SEROTONIN | SB-742457 | RATING-SCALE | VALIDITY | Serotonin Antagonists - administration & dosage | Benzylamines - adverse effects | Humans | Middle Aged | Male | Indans - therapeutic use | Benzylamines - administration & dosage | Indoles - administration & dosage | Dose-Response Relationship, Drug | Serotonin Antagonists - adverse effects | Treatment Failure | Aged, 80 and over | Female | Drug Therapy, Combination | Accidental Falls | Alzheimer Disease - psychology | Double-Blind Method | Alzheimer Disease - drug therapy | Serotonin Antagonists - therapeutic use | Cognition - drug effects | Indoles - adverse effects | Galantamine - therapeutic use | Piperidines - therapeutic use | Cholinesterase Inhibitors - adverse effects | Indoles - therapeutic use | Aged | Rivastigmine - therapeutic use | Cholinesterase Inhibitors - therapeutic use | Benzylamines - therapeutic use | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Clinical trials | Dosage and administration | Cholinesterase inhibitors | Alzheimer's disease | Drugs | Medical research | Activities of daily living | Galantamine | Neurodegenerative diseases | Serotonin | Medical treatment | Cognitive ability | Cognition | Patients | Cholinesterase | Randomization | Safety engineering | Donepezil | Alzheimers disease | Original Investigation | Research
Journal Article
Cochrane library, ISSN 1465-1858, 2017, Volume 2017, Issue 9, p. CD012763
Journal Article
Journal Article
CNS Drugs, ISSN 1172-7047, 6/2013, Volume 27, Issue 6, pp. 469 - 478
...). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors... 
Pharmacotherapy | Neurology | Neurosciences | Medicine & Public Health | Psychiatry | Psychopharmacology | DEMENTIA | PSYCHIATRY | PERFORMANCE | BEHAVIORAL SYMPTOMS | COGNITIVE IMPAIRMENT | PSYCHOLOGICAL SYMPTOMS | CLINICAL NEUROLOGY | NEUROPSYCHIATRIC INVENTORY | SPANISH VERSION | DONEPEZIL | COST | CLINICAL-TRIALS | PHARMACOLOGY & PHARMACY | Excitatory Amino Acid Antagonists - therapeutic use | Excitatory Amino Acid Antagonists - pharmacokinetics | United States | Humans | Male | Alzheimer Disease - diagnosis | Dose-Response Relationship, Drug | Female | Drug Therapy, Combination | Excitatory Amino Acid Antagonists - adverse effects | Memantine - administration & dosage | Alzheimer Disease - psychology | Severity of Illness Index | Memantine - pharmacokinetics | Argentina | Double-Blind Method | Drug Administration Schedule | Alzheimer Disease - drug therapy | Excitatory Amino Acid Antagonists - administration & dosage | Treatment Outcome | Alzheimer Disease - enzymology | Cholinesterase Inhibitors - administration & dosage | Cholinesterase Inhibitors - adverse effects | Mexico | Aged | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Delayed-Action Preparations | Memantine - adverse effects | Studies | Blister packs | Nuclear magnetic resonance--NMR | Laboratories | Older people | Compensation | Clinical trials | Clinical medicine | Pharmaceutical industry | Drug dosages | Patients
Journal Article
Journal Article
Journal of Alzheimer's Disease, ISSN 1387-2877, 2014, Volume 39, Issue 2, pp. 423 - 440
Despite three decades of intensive research in the field of Alzheimer's disease (AD) and numerous clinical trials of new therapeutic agents, cholinesterase inhibitors... 
rivastigmine | phenserine | donepezil | cholinesterase inhibitors (ChEIs) | carbamylating ChEIs | Alzheimer's disease | Add-on therapy | peripheral anionic site | FIBRIL FORMATION | ACETYLCHOLINESTERASE ACTIVITY | CEREBROSPINAL-FLUID | EPSILON-4 ALLELE | NEUROSCIENCES | COGNITIVE FUNCTION | DONEPEZIL TREATMENT | PROTEIN-LEVELS | AMYLOID-BETA-PEPTIDE | ALZHEIMERS-DISEASE PATIENTS | TRANSGENIC MICE | Cholinesterase Inhibitors - pharmacokinetics | Follow-Up Studies | Humans | Cholinesterase Inhibitors - chemistry | Acetylcholinesterase - cerebrospinal fluid | Fluorescence | Indans - therapeutic use | Physostigmine - administration & dosage | Butyrylcholinesterase - cerebrospinal fluid | Time Factors | Amyloid beta-Peptides - metabolism | Thiazoles | Amyloid beta-Peptides - cerebrospinal fluid | Piperidines - pharmacokinetics | Indans - administration & dosage | Drug Therapy, Combination | Indans - chemistry | Physostigmine - analogs & derivatives | Piperidines - administration & dosage | Piperidines - chemistry | Double-Blind Method | Alzheimer Disease - drug therapy | Physostigmine - pharmacokinetics | Alzheimer Disease - cerebrospinal fluid | Physostigmine - therapeutic use | Blotting, Western | Cholinesterase Inhibitors - administration & dosage | Piperidines - therapeutic use | Physostigmine - chemistry | Cholinesterase Inhibitors - therapeutic use | Indans - pharmacokinetics
Journal Article
Toxicology and applied pharmacology, ISSN 0041-008X, 2014, Volume 281, Issue 3, pp. 254 - 265
...) poisoning in the United States (U.S.) is the administration of atropine in combination with an oxime antidote (2-PAM Cl... 
Oxime | Efficacy | Guinea pig | Intramuscular | Toxicity | HYDROXAMIC ACIDS | PYRIDINIUM OXIMES | SOMAN | HUMAN ACETYLCHOLINESTERASE | NERVE AGENTS | TABUN | IN-VIVO REACTIVATION | CYCLOSARIN | SARIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | BRAIN | Atropine - therapeutic use | Cholinesterase Reactivators - administration & dosage | Cholinesterase Inhibitors - toxicity | Atropine - adverse effects | Oximes - adverse effects | Muscarinic Antagonists - adverse effects | Cholinesterase Inhibitors - chemistry | Oximes - administration & dosage | Pyridinium Compounds - administration & dosage | Pyridinium Compounds - therapeutic use | Oximes - therapeutic use | Male | Organophosphate Poisoning - drug therapy | Pyridinium Compounds - adverse effects | Antidotes - administration & dosage | Muscarinic Antagonists - therapeutic use | Chemical Warfare Agents - chemistry | Cholinesterases - blood | Organophosphate Poisoning - physiopathology | Drug Therapy, Combination - adverse effects | Injections, Subcutaneous | Cholinesterase Reactivators - adverse effects | Guinea Pigs | Drug Administration Schedule | Cholinesterase Reactivators - therapeutic use | Injections, Intramuscular | Pesticides - antagonists & inhibitors | Random Allocation | Muscarinic Antagonists - administration & dosage | Animals | Cholinesterase Inhibitors - administration & dosage | Pesticides - toxicity | Organophosphate Poisoning - blood | Antidotes - adverse effects | Atropine - administration & dosage | Chemical Warfare Agents - toxicity | Drug Monitoring | Antidotes - therapeutic use | Analysis | Enzyme inhibitors | Pesticides | Index Medicus | CHOLINESTERASE | ATROPINE | GUINEA PIGS | CHLORINE | BLOOD-BRAIN BARRIER | CENTRAL NERVOUS SYSTEM | SYMPTOMS | TOXICITY | STANDARD OF LIVING | US FDA | 60 APPLIED LIFE SCIENCES | MOLECULAR WEIGHT | PESTICIDES | LETHAL DOSES | OXIMES | THERAPY | CHEMICAL WARFARE AGENTS | POISONING | BLOOD | toxicity | intramuscular | guinea pig | oxime | efficacy
Journal Article
Journal Article